569 related articles for article (PubMed ID: 33721558)
21. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
Siegel CA; Melmed GY; McGovern DP; Rai V; Krammer F; Rubin DT; Abreu MT; Dubinsky MC; ;
Gut; 2021 Apr; 70(4):635-640. PubMed ID: 33472895
[No Abstract] [Full Text] [Related]
22. How protein-based COVID vaccines could change the pandemic.
Dolgin E
Nature; 2021 Nov; 599(7885):359-360. PubMed ID: 34750543
[No Abstract] [Full Text] [Related]
23. Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines-Correlates of Immunogenicity Parameters with Protection.
Vajo Z
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215791
[TBL] [Abstract][Full Text] [Related]
24. [We must respect the anti-SARS-CoV-2 vaccine schedule without delay in cancer patients under treatment].
Barrière J; Audigier-Valette C; Borchiellini D; Hoch B; Castelnau O; Francois E; Gastaud L; Skaf R; Berdah JF; Marie W; Lescaut W; Peyrade F; Cluzeau T; Cassuto O; Carles M
Bull Cancer; 2021 Apr; 108(4):341-342. PubMed ID: 33741139
[No Abstract] [Full Text] [Related]
25. FDA authorizes first single-shot COVID-19 vaccine.
Mullard A
Nat Rev Drug Discov; 2021 Apr; 20(4):251. PubMed ID: 33707753
[No Abstract] [Full Text] [Related]
26. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.
Banga Ndzouboukou JL; Zhang YD; Lei Q; Lin XS; Yao ZJ; Fu H; Yuan LY; Fan XL
Curr Med Sci; 2021 Dec; 41(6):1081-1086. PubMed ID: 34741251
[TBL] [Abstract][Full Text] [Related]
27. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
[TBL] [Abstract][Full Text] [Related]
28. How COVID unlocked the power of RNA vaccines.
Dolgin E
Nature; 2021 Jan; 589(7841):189-191. PubMed ID: 33437061
[No Abstract] [Full Text] [Related]
29. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy.
Wang Y; Yang C; Song Y; Coleman JR; Stawowczyk M; Tafrova J; Tasker S; Boltz D; Baker R; Garcia L; Seale O; Kushnir A; Wimmer E; Mueller S
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34193524
[TBL] [Abstract][Full Text] [Related]
30. Targets and strategies for vaccine development against SARS-CoV-2.
Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
[TBL] [Abstract][Full Text] [Related]
31. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
32. Can COVID-19 vaccines stop the pandemic?
Lau CS
Hong Kong Med J; 2021 Apr; 27(2):84-85. PubMed ID: 33879622
[No Abstract] [Full Text] [Related]
33. A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization.
Mattoo SS; Myoung J
J Microbiol Biotechnol; 2021 Dec; 31(12):1601-1614. PubMed ID: 34949742
[TBL] [Abstract][Full Text] [Related]
34. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine.
Beharier O; Plitman Mayo R; Raz T; Nahum Sacks K; Schreiber L; Suissa-Cohen Y; Chen R; Gomez-Tolub R; Hadar E; Gabbay-Benziv R; Jaffe Moshkovich Y; Biron-Shental T; Shechter-Maor G; Farladansky-Gershnabel S; Yitzhak Sela H; Benyamini-Raischer H; Sela ND; Goldman-Wohl D; Shulman Z; Many A; Barr H; Yagel S; Neeman M; Kovo M
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34014840
[TBL] [Abstract][Full Text] [Related]
35. COVID vaccine immunity is waning - how much does that matter?
Dolgin E
Nature; 2021 Sep; 597(7878):606-607. PubMed ID: 34548661
[No Abstract] [Full Text] [Related]
36. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
37. Combined Vaccination Approaches for COVID-19. Will These Improve the Efficacy Spectrum?
Van Dreden P; Fareed J; Elalamy I; Gerotziafas G
Clin Appl Thromb Hemost; 2021; 27():10760296211033906. PubMed ID: 34689575
[No Abstract] [Full Text] [Related]
38. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
39. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
[No Abstract] [Full Text] [Related]
40. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
